Biotech Adam Feuerstein and Damian Garde STAT Plus: Q&A: How biotech analysts navigate fickle markets, pushy investors, and ‘vindictive’ CEOs
Politics Erin Mershon STAT Plus: House poised to pass bill critical for drug industry; the Senate may be a slog
Politics Dylan Scott STAT Plus: Under fire from Trump, drug industry lands Oval Office meeting on Tuesday
First Opinion Dana P. Goldman and Darius Lakdawalla Election verdict: Pharma needs a new prescription
First Opinion Henry A. Waxman and Bill Corr Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs
Business Damian Garde STAT Plus: The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes
In the Lab Helen Branswell The race for a Zika vaccine is intense. But it may be missing the most important players
The Pharmalot View Ed Silverman The ‘gouge factor’: Big companies want transparency in drug price negotiations
Business Charles Ornstein and Ryann Grochowski Jones — ProPublica Drug and device makers find receptive audience at for-profit, Southern hospitals
Biotech Meghana Keshavan and Rebecca Robbins Post-Brexit, will the European Medicines Agency be homeless?